Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The platelet aggregation pathway orchestrates the rapid recruitment and cross-linking of activated platelets at sites of vascular damage through integrins like αIIbβ3 interacting with plasma proteins such as fibrinogen and vWF—processes modulated by complex intracellular signals triggered by multiple agonists acting on diverse surface receptors. This redundancy ensures effective hemostasis but also presents targets for therapeutic intervention in thrombotic diseases.
Inhibition of platelet activation and aggregation via various mechanisms (e.g., COX-1 inhibition, P2Y12 receptor antagonism, GPIIb/IIIa receptor blockade).
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Platelet Aggregation Pathway.